Ionis Pharmaceuticals (NASDAQ:IONS) EVP Eugene Schneider Sells 9,302 Shares of Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eugene Schneider sold 9,302 shares of the stock in a transaction on Friday, January 16th. The stock was sold at an average price of $75.59, for a total value of $703,138.18. Following the transaction, the executive vice president directly owned 63,890 shares in the company, valued at $4,829,445.10. The trade was a 12.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Ionis Pharmaceuticals Stock Performance

IONS stock opened at $77.53 on Wednesday. The company has a debt-to-equity ratio of 0.96, a current ratio of 2.79 and a quick ratio of 2.78. The business has a 50-day moving average price of $78.90 and a 200 day moving average price of $64.33. The company has a market capitalization of $12.56 billion, a P/E ratio of -45.88 and a beta of 0.28. Ionis Pharmaceuticals, Inc. has a 1-year low of $23.95 and a 1-year high of $86.15.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Wednesday, October 29th. The company reported ($0.80) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.35. The company had revenue of $156.72 million during the quarter, compared to the consensus estimate of $131.75 million. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 44.26%. Ionis Pharmaceuticals’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.95) earnings per share. As a group, equities research analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital World Investors raised its holdings in Ionis Pharmaceuticals by 1.5% in the 3rd quarter. Capital World Investors now owns 12,722,728 shares of the company’s stock worth $832,321,000 after purchasing an additional 182,540 shares during the period. Adage Capital Partners GP L.L.C. grew its holdings in Ionis Pharmaceuticals by 253.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,800,000 shares of the company’s stock valued at $150,138,000 after purchasing an additional 2,724,400 shares during the period. Tweedy Browne Co LLC raised its stake in shares of Ionis Pharmaceuticals by 0.3% during the 3rd quarter. Tweedy Browne Co LLC now owns 2,901,216 shares of the company’s stock worth $189,798,000 after buying an additional 9,268 shares during the period. Geode Capital Management LLC lifted its position in shares of Ionis Pharmaceuticals by 1.7% during the 2nd quarter. Geode Capital Management LLC now owns 2,891,095 shares of the company’s stock valued at $114,245,000 after buying an additional 48,141 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in shares of Ionis Pharmaceuticals by 190.3% during the 3rd quarter. American Century Companies Inc. now owns 1,372,225 shares of the company’s stock valued at $89,771,000 after buying an additional 899,476 shares in the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Analyst Ratings Changes

IONS has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research note on Wednesday, October 8th. Barclays upped their price objective on shares of Ionis Pharmaceuticals from $80.00 to $95.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Guggenheim lifted their target price on shares of Ionis Pharmaceuticals from $90.00 to $92.00 and gave the stock a “buy” rating in a research note on Tuesday, September 23rd. Stifel Nicolaus boosted their target price on shares of Ionis Pharmaceuticals from $43.00 to $67.00 and gave the stock a “hold” rating in a research report on Monday, October 6th. Finally, Wells Fargo & Company upped their price target on shares of Ionis Pharmaceuticals from $82.00 to $100.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $87.05.

Trending Headlines about Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Analyst / media bullishness on olezarsen: A recent Seeking Alpha piece highlights an expected 2026 launch of olezarsen in SHTG and argues that approval/commercial rollout could drive a substantial revenue inflection for Ionis; the article notes strong recent momentum and positions olezarsen as the key upside catalyst. Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
• Neutral Sentiment: Trading and technicals: Intraday volume is elevated (~4.9M shares vs. a ~1.5M average), suggesting the market is actively reacting to the news flow; the stock is above its 200‑day moving average (support) but near the 50‑day average—momentum could depend on upcoming clinical/commercial milestones.
• Negative Sentiment: Large, concentrated insider selling: Multiple executives (including CEO Brett P. Monia and several EVPs) sold shares on Jan 16 totaling roughly 117K shares (~$8.8M) — CEO sale (~44K shares, ~$3.3M) and several EVP sales of ~8–13K shares each. These filings can be reviewed in the SEC disclosures, which may signal tax/diversification activity but can also weigh on sentiment.
  Bennett filing
  Birchler filing
  Devers filing
  Hougen filing
  Jenne filing
  Kordasiewicz filing
  Monia (CEO) filing
  O’neil filing
  Schneider filing
  Swayze filings

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.